troglitazone has been researched along with Shock in 1 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Shock: A pathological condition manifested by failure to perfuse or oxygenate vital organs.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Maggi, LB | 1 |
| Sadeghi, H | 1 |
| Weigand, C | 1 |
| Scarim, AL | 1 |
| Heitmeier, MR | 1 |
| Corbett, JA | 1 |
1 other study available for troglitazone and Shock
| Article | Year |
|---|---|
Anti-inflammatory actions of 15-deoxy-delta 12,14-prostaglandin J2 and troglitazone: evidence for heat shock-dependent and -independent inhibition of cytokine-induced inducible nitric oxide synthase expression.
Topics: Animals; Anti-Inflammatory Agents; Cell Line; Chromans; Cytokines; Hot Temperature; Interferon-gamma | 2000 |